Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kirin Establishes Local Subsidiary in Thailand
June 20, 2005
- France Invites Investments
June 20, 2005
- BUSINESS NEWS IN BRIEF
June 20, 2005
- NEW PRODUCTS
June 20, 2005
- Draft Basic Policy 2005 for Reform Announced
June 20, 2005
- LDP to Compile Priority Issues for Gov't Basic Policy 2005
June 20, 2005
- MOF Council Recommends "Urgent Measures" to Control Healthcare Benefits
June 20, 2005
- FPMAJ Members Exchange Views on Soseki Required by New PAL
June 20, 2005
- DPC Classification for 3 Treatments to Be Reviewed
June 20, 2005
- More Clinical Trials Needed in Japan: PFSB Director General
June 20, 2005
- REGULATORY NEWS IN BRIEF
June 20, 2005
- Forerunner Pharma Research Created by Chugai and 2 Other Firms
June 20, 2005
- JHSF Reports Results of Activities to Support Clinical Trials
June 20, 2005
- HEALTH FOOD/OTC NEWS IN BRIEF
June 13, 2005
- STATISTICS
June 13, 2005
- MEDICAL DEVICE NEWS IN BRIEF
June 13, 2005
- JMED Approves FY2005 Business Plan
June 13, 2005
- R&D NEWS IN BRIEF
June 13, 2005
- Peg-IFN + Ribavirin to Become the Mainstay for Genotype 1 HCV with High Viral Load: Expert
June 13, 2005
- JHSF Technology Transfer Center to Conclude 1st Patent License Agreement
June 13, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…